Stock Events

Bone Biologics 

$3.71
17
+$0.56+17.91% Today

Statistics

Day High
-
Day Low
-
52W High
86.81
52W Low
2.86
Volume
53,159
Avg. Volume
38,564
Mkt Cap
11.96M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MarExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
-3.04
-2.03
-1.01
0
Expected EPS
-0.7
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BBLG. It's not an investment recommendation.

About

Biotechnology
Health Technology
Pharmaceuticals: Major
Other Services (except Public Administration)
Professional Organizations
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
Show more...
CEO
Employees
2
Country
US
ISIN
US0980703039

Listings